25th Apr 2005 07:00
Sinclair Pharma PLC25 April 2005 SINCLAIR PHARMA PLC SINCLAIR APPOINTS CHIEF OPERATING OFFICER Godalming UK, 25 April 2005: Sinclair Pharma plc ("Sinclair" or the "Company")(SPH.L), the specialty pharmaceutical company, are pleased to announce theappointment of Derek Williams as Chief Operating Officer of SinclairPharmaceuticals Ltd, the operating company of Sinclair Pharmaceuticals Plc,effective immediately. Mr Williams has over fifteen years of senior commercial management experience inthe global pharmaceutical industry and joins Sinclair from Celltech where he wasmost recently European Commercial Director, overseeing the restructuring ofcommercial operations and the establishment of a Europe-wide secondary carecapability. Prior to that, Mr Williams was Senior Vice President of GlobalStrategic Marketing at Bayer, based in the USA and has held general managementpositions in both the pharmaceutical and medical diagnostics industries inEurope and North America. He joins Sinclair at an exciting time for the company as the Company advancesits strategy to establish its own presence in key markets in order to improvemargins. The recent acquisition of Euroderm in Italy represents the first stepin this process and the Company has initiated discussions for acquisitions inother key EU markets. Mr Williams' role will be to lead Sinclair's expansion ofits own sales and marketing capability across Europe and into North America asmore of the products in the company's pipeline come to market. Dr Michael Flynn, CEO of Sinclair Pharma, said: "I am delighted to welcome Derekto Sinclair. Derek brings invaluable industry experience and in particularsubstantial strategic and commercialisation experience. I am sure he will be agreat asset to Sinclair as we advance the business." ENDS Enquiries: Sinclair Pharma plcDr Michael Flynn, CEO Tel: 01483 426 644John Barrington-Carver (Media Enquiries) Tel: 07831 655 630 Financial DynamicsBen Atwell / Lucy Briggs Tel: 0207 831 3113 Notes to editors: Sinclair Pharma plc Sinclair Pharma plc based in Godalming in the UK, is quoted on the AlternativeInvestment Market (AIM) on the London Stock Exchange and has focused on theacquisition and development of niche patented pharmaceutical products in thefields of oral health, oncology support and dermatology, and bringing them tothe international market place via out-licensing partners. The Company combinesproduct evaluation, product development, regulatory and business developmentexpertise to add value to its acquired and in-house developed products. A keyelement of the Sinclair business model is to minimise risk and exposure byavoiding involvement in lengthy R&D programmes and rapidly achieving globaldistribution through a network of marketing partners. The Company has alreadylicensed its products for distribution in over 40 countries around the world. On 4th January 2005 Sinclair announced its first Decapinol(R) deal with Dompe SAfor the Italian market in an agreement involving almost 1.5 million Euros inupfront and milestone payments and a supply agreement with minimum purchaseobligations. In February the Company announced it had concluded its seconddistribution agreement for Decapinol(R) having licensed it to the Spanishcompany Inibsa. For more information: www.sinclairpharma.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma